Universe Pharmaceuticals (NASDAQ:UPC) Shares Up 2.7% – Should You Buy?

Universe Pharmaceuticals INC (NASDAQ:UPC)’s share price rose 2.7% during mid-day trading on Tuesday . The company traded as high as $4.95 and last traded at $4.53. Approximately 58,817 shares traded hands during mid-day trading, an increase of 163% from the average daily volume of 22,381 shares. The stock had previously closed at $4.41.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Universe Pharmaceuticals Trading Up 2.7%

The stock’s fifty day simple moving average is $4.12 and its two-hundred day simple moving average is $4.18.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.